2. Amgen Inc. (NASDAQ:AMGN)
Number of Hedge Fund Holders: 52
Dividend Yield as of February 9: 3.27%
Glenview Capital’s Stake Value: $22,513,000
Amgen Inc. (NASDAQ:AMGN) is an American biopharmaceutical company that specializes in human therapeutics. Appreciating the company’s recently proposed guidance, in February, both BMO Capital and Wells Fargo raised the stock’s price target to $240 and $250, respectively, with the latter maintaining an Equal Weight rating on the shares.
Two Sigma Advisors was the largest shareholder of Amgen Inc. (NASDAQ:AMGN) in Q3, owning nearly 2 million shares in the company. Overall, 52 hedge funds tracked by Insider Monkey held stakes in the company in Q3, down from 53 in the preceding quarter. These stakes hold a value of around $1.45 billion.
On December 3, 2021, Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend of $1.94 per share, presenting a 10.2% growth from the previous dividend. The stock’s dividend yield stands at 3.27%. Amgen Inc. (NASDAQ:AMGN) has been paying dividends to shareholders consistently for the past 11 years, with a five-year CAGR of 11.97%. In Q3 2021, Glenview Capital increased its position in Amgen Inc. (NASDAQ:AMGN) by 47% and held shares worth over $22.5 million. The company accounted for 0.41% of Larry Robbins’ portfolio.
ClearBridge Investments mentioned Amgen Inc. (NASDAQ:AMGN) in its recently-published Q3 2021 investor letter. Here is what the firm has to say:
“In health care, Amgen, a biotechnology company, has endured several pipeline setbacks recently, including a slow transition of its Lumakras treatment into first-line lung cancer, a slower than expected development of its treatment for myeloma as well as the company’s asthma treatment Tezepelumab missing its primary endpoint in a Phase III study. We remain positive on the stock, with Amgen’s investments in biosimilars and its pipeline part of our long-term thesis.”
